Dublin, March 06, 2024 (GLOBE NEWSWIRE) -- The "Capecitabine Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.
The capecitabine market size is expected to see strong growth in the next few years. It will grow to $3.14 billion in 2028 at a compound annual growth rate (CAGR) of 8.7%. The anticipated growth in the forecast period can be attributed to factors such as expanded indications for capecitabine, ongoing research in combination therapies, development of healthcare infrastructure, government initiatives supporting cancer care, and increased adoption in developing countries. Notable trends expected in the forecast period include the exploration of targeted therapy combinations, expanded use in adjuvant settings, the integration of biomarker-driven treatment approaches, advancements in pharmacogenomics, and the implementation of telehealth monitoring in cancer care. These trends indicate a dynamic landscape with a focus on personalized and comprehensive approaches to cancer treatment.
The upsurge in clinical trials stands poised to significantly impact the growth trajectory of the capecitabine market. Clinical trials, pivotal research studies evaluating the safety and efficacy of medical interventions or drugs in human subjects, play a crucial role in assessing capecitabine's potential across diverse cancer types. These trials constitute a fundamental phase in the drug development process, providing essential data for regulatory approval and eventual public use.
The trend of product innovations has gained significant traction. Notably, major companies operating within the capecitabine market have directed their efforts towards developing generic tablets as a strategic approach to augment their revenues. A prime example occurred in February 2021 when Dr. Reddy's Laboratories, an India-based pharmaceutical company, introduced Capecitabine tablets - an FDA-approved generic variant of Xeloda - into the United States market. Specifically utilized in cancer treatment, these tablets are available in 150 mg and 500 mg strengths, offered in bottle counts of 60 and 120, respectively.
A selection of companies mentioned in this report includes
- Pfizer Inc.
- Merck & Co. Inc.
- Bayer AG
- Novartis AG
- Sanofi S.A.
- Sensus Healthcare Inc.
- Fresenius SE & Co. KGaA
- GlaxoSmithKline plc
- Eli Lilly and Company
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Inc.
- Genentech Inc.
- Aurobindo Pharma Limited
- Dr Reddy Laboratories Ltd.
- Sigma-Aldrich Corp
- Cipla Inc.
- Hikma Pharmaceuticals plc
- Lupin Limited
- Alkem Laboratories Limited
- Ranbaxy Laboratories Ltd.
- Glenmark Pharmaceuticals Ltd.
- Accord Healthcare Ltd.
- Zentiva N.V.
- Reliance Life Sciences Pvt Ltd.
- Avita Medical Limited
- Mylan Inc.
- Sandoz Inc.
For more information about this report visit https://www.researchandmarkets.com/r/gmtx9s
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
